NewLink Genetics Announces Presentation of Two Abstracts at AACR
- Clinical Trials Plenary Session: Abstract CT117 - Interim analysis of the Phase 2 clinical trial of the IDO pathway inhibitor indoximod in combination with pembrolizumab for patients with advanced melanoma, to be presented during the Novel Immuno-Oncology Agent Clinical Trials session,
Tuesday April 4, 2017 10:30 a.m. - 12:45 p.m. ET . - Poster Session: Abstract 4076 - A novel prodrug of indoximod with enhanced pharmacokinetic properties, to be presented during poster session PO.ET05.01 - Mechanistic Understanding of Novel Anticancer Therapies,
April 4, 2017 1 p.m. - 5 p.m. ET .
The complete text of Clinical Plenary Session abstracts that have not been selected for the press program will be posted online at
"We are honored to have been selected by the AACR review committee for the Clinical Trials Plenary Session at the upcoming AACR meeting," said
About
NewLink Genetics is a biopharmaceutical company at the forefront of discovering, developing and commercializing novel immuno-oncology product candidates to improve the lives of patients with cancer. NewLink Genetics' product candidates are designed to harness multiple components of the immune system to combat cancer. For more information, please visit http://www.newlinkgenetics.com
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements of NewLink that involve substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements, within the meaning of The
Private Securities Litigation Reform Act of 1995. The words "anticipate," "believe," "estimate," "expect," "intend," "may," "plan," "target," "potential," "will," "could," "should," "seek" or the negative of these terms or other similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. These forward-looking statements include, among others, statements about results of its clinical trials for product candidates; its timing of release of data from ongoing clinical studies; its plans related to moving additional indications into clinical development; and any other statements other than statements of historical fact. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements that NewLink makes due to a number of important
factors, including those risks discussed in "Risk Factors" and elsewhere in
Investors:Source:Beth Kurth LaVoieHealthScience 617-374-8800, ext. 106 bkurth@lavoiehealthscience.com Media:Alison Chen LaVoieHealthScience 617-374-8800, ext. 104 achen@lavoiehealthscience.com
News Provided by Acquire Media